Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Urbano-Ispizua, Alvaro  [Clear All Filters]
2023
Ruiz-Boy S, Pedraza A, Prat M, Salas MQueralt, Carcelero E, Riu-Viladoms G, Suárez-Lledó M, Monge-Escartín I, Rodríguez-Lobato LGerardo, Martínez-Roca A, et al. At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program. Pharmaceuticals (Basel). 2023;16(12).
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.
Sanchez-Guijo F, Avendaño-Solá C, Badimon L, Bueren JA, Canals JM, Delgadillo J, Delgado J, Eguizabal C, Fernández-Santos M-E, García-Olmo D, et al. Role of Hospital Exemption in Europe: position paper from the Spanish Advanced Therapy Network (TERAV). Bone Marrow Transplant. 2023.
2022
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
2020
Rodríguez-Lobato L-G, Martínez-Roca A, Castaño-Díez S, Palomino-Mosquera A, Gutiérrez-García G, Pedraza A, Suárez-Lledó M, Rovira M, Martínez C, de Larrea CFernández, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS One. 2020;15(11):e0241778.
Ortíz-Maldonado V, Rives S, Castellà M, Alonso-Saladrigues A, Benitez-Ribas D, Caballero-Baños M, Baumann T, Cid J, Garcia-Rey E, Llanos C, et al. CART19-BE-01: A Multicenter Trial of ARI-0001 Cell Therapy in Patients with CD19 Relapsed/Refractory Malignancies. Mol Ther. 2020.
Im A, Rashidi A, Wang T, Hemmer M, MacMillan ML, Pidala J, Jagasia M, Pavletic S, Majhail NS, Weisdorf D, et al. Risk Factors for Graft-versus-Host Disease in Haploidentical Hematopoietic Cell Transplantation Using Post-Transplant Cyclophosphamide. Biol Blood Marrow Transplant. 2020.
2019
Gutiérrez-García G, Cibeira MTeresa, Rovira M, de Larrea CFernández, Tovar N, Rodríguez-Lobato LGerardo, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019.
Suárez-Lledó M, Marcos MAÁngeles, Cuatrecasas M, Bombi JAntoni, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, et al. Quantitative PCR is faster, more objective and more reliable than immunohistochemistry for the diagnosis of Cytomegalovirus Gastrointestinal disease in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019.
2018
Chhabra S, Liu Y, Hemmer MT, Costa L, Pidala JA, Couriel DR, Alousi AM, Majhail NS, Stuart RK, Kim D, et al. Comparative analysis of calcineurin-inhibitor-based methotrexate and mycophenolate mofetil-containing regimens for prevention of Graft-versus-Host Disease after reduced intensity conditioning allogeneic transplantation. Biol Blood Marrow Transplant. 2018.
2014
Arora M, Hemmer MT, Ahn KWoo, Klein JP, Cutler CS, Urbano-Ispizua A, Couriel DR, Alousi AM, Gale RPeter, Inamoto Y, et al. CIBMTR Chronic GVHD Risk Score Predicts Mortality in an Independent Validation Cohort. Biol Blood Marrow Transplant. 2014.